Christie’s COVID-19 treatment raises fairness, safety questions

Former New Jersey Gov. Chris Christie’s treatment for COVID-19 raises questions about the fairness of decisions to grant access to investigational therapies, as well as the safety of exposing patients to untested drug combinations.

Instead of being treated with a mAb product from  Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) that is being tested at the facility where he was hospitalized, Christie received a mAb cocktail that Eli Lilly and Co. (NYSE:LLY) is testing in COVID-19 patients who have less severe symptoms. ...